[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499287":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":108,"collaborators":26,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":112,"sex":118,"minAge":26,"maxAge":119,"enrollmentInfo":120,"targetDuration":26,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Institut Curie","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TauroLock™","EXPERIMENTAL","The patient will be followed up to a maximum of 6 months after randomization after have a Taurlock™ injected each time catheter will be used.",[13],"Device: TaurolockTM",{"label":15,"type":16,"description":17,"interventionNames":18},"Physiological serum (NaCl 0.9%)","PLACEBO_COMPARATOR","The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.",[19],"Device: Physiological serum",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","TaurolockTM","The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Physiological serum",[15],[31],{"name":32,"affiliation":5,"role":33},"Camille CORDERO, MD","STUDY_DIRECTOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+33172389309","camille.cordero@curie.fr",{"name":40,"role":36,"phone":26,"phoneExt":26,"email":41},"Marie-Emmanuelle Legrier, PhD","drci.promotion@curie.fr",[43,61,72,83,94],{"facility":5,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Paris","75005","France","FR",{"type":50,"coordinates":51},"Point",[52,53],2.3488,48.85341,{"lat":53,"lon":52},[56,59],{"name":57,"role":36,"phone":26,"phoneExt":26,"email":58},"Lauriane LEMELLE, MD","lauriane.lemelle@curie.fr",{"name":57,"role":60,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":62,"status":44,"city":45,"state":26,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Saint Louis","75010",{"type":50,"coordinates":65},[52,53],{"lat":53,"lon":52},[68,71],{"name":69,"role":36,"phone":26,"phoneExt":26,"email":70},"Florence RABIAN, MD","florence.rabian@aphp.fr",{"name":69,"role":60,"phone":26,"phoneExt":26,"email":26},{"facility":73,"status":44,"city":45,"state":26,"zip":74,"country":47,"countryCode":48,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Armand Trousseau","75012",{"type":50,"coordinates":76},[52,53],{"lat":53,"lon":52},[79,82],{"name":80,"role":36,"phone":26,"phoneExt":26,"email":81},"Arnaud PETIT, MD","arnaud.petit@aphp.fr",{"name":80,"role":60,"phone":26,"phoneExt":26,"email":26},{"facility":84,"status":44,"city":45,"state":26,"zip":85,"country":47,"countryCode":48,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"Robert Debre","75935",{"type":50,"coordinates":87},[52,53],{"lat":53,"lon":52},[90,93],{"name":91,"role":36,"phone":26,"phoneExt":26,"email":92},"Benoit BRETHON, MD","benoit.brethon@aphp.fr",{"name":91,"role":60,"phone":26,"phoneExt":26,"email":26},{"facility":95,"status":44,"city":96,"state":26,"zip":97,"country":47,"countryCode":48,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Gustave Roussy","Villejuif","94805",{"type":50,"coordinates":99},[100,101],2.35992,48.7939,{"lat":101,"lon":100},[104,107],{"name":105,"role":36,"phone":26,"phoneExt":26,"email":106},"Charlotte RIGAUD, MD","charlotte.rigaud@gustaveroussy.fr",{"name":105,"role":60,"phone":26,"phoneExt":26,"email":26},{"type":109,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100499287","multicentre-randomised-study-comparing-a-taurolidine-lock-and-a-standard-saline-lock-in-paediatric-oncology-100499287",false,"NCT05781295","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.","PEDIALOCK","Inclusion Criteria:\n\n1. Patient less than or equal to 21 years of age at inclusion.\n2. Patient for whom a central catheter is planned to be inserted\\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \\*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).\n3. Patient treated for a cancer.\n4. Patient with regular follow-up in the inclusion center.\n5. Informed consent signed by the patient if adult or by legal representatives if minor.\n6. Patient benefiting from a social security coverage.\n7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.\n\nExclusion Criteria:\n\n1. Patient with retinoblastoma.\n2. Allografted patient.\n3. Patient with a life expectancy of less than 6 months.\n4. Patient refusing to participate in the protocol.\n5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).\n6. Patient with known allergy to citrate or (cyclo)-Taurolidine.\n7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.\n8. Patient with an external femoral catheter.\n9. Patient with a PICCLINE-type peripheral venous inserted central catheter.\n10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.\n11. Patient under guardianship and curatorship.","ALL","21 Years",{"count":121,"type":122},148,"ESTIMATED","INTERVENTIONAL",[125],"NA","Interest of a Taurolidine lock at each catheter closure in the primary prevention of catheter-related endoluminal infection in paediatric oncology.\n\nMulticentric, controlled, randomized and double-blind label study.",[128,129,130,131],"Children","Medical Device","Primary Prevention","Oncology","2026-02-18",{"date":134,"type":135},"2026-02-20","ACTUAL",{"date":137,"type":135},"2024-01-19",{"date":139,"type":122},"2028-07-23",{"name":5,"class":6},5]